Biogen Idec Bolsters MS, Oncology Pipeline Via PDL Co-Development Pact
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Biogen Idec will leverage its multiple sclerosis and oncology franchises to co-develop Protein Design Labs’ daclizumab and volociximab for MS and cancer applications under a deal worth up to $800 mil.